{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069193","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.371569+00:00","generated_at":"2026-06-07T15:13:59.290886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexeo completes IPO raising $111.5M; Q3 net loss $20.1M as programs advance","bullets":["IPO in November 2023 raised $111.5M gross; pro forma cash $136.4M, funding operations into Q4 2025.","Completed enrollment of all four cohorts in LEAD Phase 1/2 trial of LX1001 for APOE4-Alzheimer's.","Received Canadian CTA clearance for LX2006 (FA cardiomyopathy); first non-US site activated.","Net loss Q3 2023: $20.1M ($12.36 per share) vs $17.1M ($10.38) in Q3 2022; R&D spend $17.2M.","Sandi See Tai, M.D. joined as SVP Clinical Development and Operations in October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069193","json":"https://secwatch.observer/filing/0000950170-23-069193.json","markdown":"https://secwatch.observer/filing/0000950170-23-069193.md","text":"https://secwatch.observer/filing/0000950170-23-069193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/0000950170-23-069193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/lxeo-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:13:59.290886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93241267a5cd819a0c21ae808b6b7bb93f7f099e","claim":"Lexeo Therapeutics, Inc. reported financial results for the three and nine-months ended September 30, 2023.","evidence_excerpt":"On December 11, 2023, Lexeo Therapeutics, Inc. (the \" Registrant \") issued a press release announcing business highlights and its financial results for the three and nine-months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1907108/000095017023069193/0000950170-23-069193-index.htm","confidence":0.5,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine-months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}